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Introduction: Alexithymia may moderate the effectiveness of treatment and may predict
impaired general functioning of patients suffering from somatic symptom and related
disorders (SSRD).
Aim:We compared alexithymia levels in a clinical prospective study with 234 consecutive
patients suffering from SSRD from the Centre of Excellence for Body, Mind, and Health,
Tilburg using the Bermond-Vorst Alexithymia Questionnaire, with general population
norm scores. Second, we explored treatment outcomes of a multimodal treatment
tailored to patient needs by Shared Decision Making (SDM) and Patient Related Outcome
Monitoring (PROM) in patients with SSRD. Third, we explored whether alexithymia
is associated with treatment outcome. Fourth, we explored if the presence of a
chronic medical condition (e.g., diabetes mellitus, cardiovascular diseases) affects the
association of alexithymia with treatment outcomes.
Results: Compared to norm scores, SSRD patients showed elevated scores on the
subscales identifying, verbalizing, and fantasizing, and on the cognitive dimension.
All patients benefited from treatment in terms of anxiety, depression, and physical
symptoms. The association of alexithymia with treatment outcome was significant,
but the effect size was negligible (range odds ratios 1.02–1.25). The association
between alexithymia and treatment outcome was stronger in patients suffering from
chronic medical conditions compared to patients without chronic medical conditions.
However, the effect size of this association was negligible (range odds ratio 0.94–1.12).
de Vroege et al. Alexithymia and Treatment Outcome in SSRD
Discussion: Alexithymia scores are elevated in patients with SSRD compared to general
population scores, but the level of alexithymia has no clinically relevant association with
treatment outcome both in SSRD patients with and without comorbid chronic medical
conditions.
Keywords: alexithymia, treatment outcome, somatic symptom and related disorders, depression, anxiety, physical
symptoms, general functioning
INTRODUCTION
Nemiah and Sifneos (1) introduced the concept of alexithymia
to describe an emotional deficiency in patients with classic
psychosomatic disorders, such as asthma, and hypertension.
Patients were unaware of their feelings or were incapable
to verbalize them, and they were unable to fantasize about
their inner thoughts, feelings, and attitudes. Although the
concept originated from psychoanalytical research, in time it
also incorporated other perspectives, such as those originating
from cognitive behavioral research and from stress research.
In the 1990s, alexithymia was described as a combination of
the following features: (a) difficulty identifying and describing
feelings, (b) difficulty distinguishing feelings and bodily
sensations caused by emotional arousal, (c) constricted
imaginal processes, and (d) a cognitive style characterized
by a preoccupation with the details of external events (2).
These characteristics are related to stress and adaptation,
and have repercussions for psychotherapeutic treatment
possibilities.
Although alexithemic patients were prepared to participate
in therapy consisting of a psychodynamic oriented multimodal
therapy (3), alexithymia has also been described as interfering
with psychotherapy (4), such as group psychotherapy, individual
psychodynamic psychotherapy, and supportive therapy. Recent
studies found that specifically focusing on alexithymia during
treatment improved treatment outcomes in terms of symptom
reduction and general functioning (5–9), but the results of
a 2013 systematic review (10) were inconclusive, and was
suggested that development of evidence-based treatments are
necessary (10). Since most psychotherapeutic approaches rely
on the patients’ access to their emotions, patients unable to
address these emotions provide a challenge for therapists. We
do not know of studies exploring the association between
alexithymia and treatment outcome at symptom level in
patients suffering from somatic symptom and related disorder
(SSRD).
Because alexithymia was found to be related to impoverished
general functioning in somatoform disorders (2, 11–21),
following the classification of the Diagnostic and Statistical
Manual of Mental Disorders (DSM)-IV-TR (22) and other
precursors of SSRD, as described in DSM-5 (23), general
functioning also may be a relevant outcome of treatment. As far
as we know, studies exploring this aspect of treatment outcome
in patients suffering from SSRD have not been done. This study
explores whether alexithymia has a moderating effect in treating
depressive, anxiety, physical symptoms, and general functioning
in SSRD patients.
OBJECTIVES AND HYPOTHESES
The first objective of this study was to estimate the level of
alexithymia of patients suffering from SSRD and compare this
level to known norm scores for the general population. We
expected the alexithymia scores of SSRD patients to be higher.
The second objective was to explore outcomes of amultimodal
treatment tailored to patient needs by Shared Decision Making
(SDM) and Patient Related Outcome Monitoring (PROM)
(24) with respect to depression, anxiety, physical symptoms,
and general functioning in patients with SSRD, independent
of alexithymia scores at baseline. We expected the treatment
outcome to be improved.
The third objective was to examine the association of
alexithymia with treatment outcomes with respect to depression,
anxiety, physical symptoms, and general functioning. We
predicted the patients with high levels of alexithymia show less
favorable treatment outcomes than patients with low levels of
alexithymia.
The fourth objective was to examine the influence of chronic
medical conditions (e.g., diabetes mellitus, cardiovascular
diseases) on the association between alexithymia and treatment
outcome. We hypothesized a stronger association between
alexithymia and treatment outcomes in patients suffering from
chronic medical condition and alexithymia than in patients
without chronic medical condition.
METHODS
Study Design
The study uses data from a longitudinal observational design
in a clinical setting. The sample existed of patients suffering
from SSRD who were treated at the Clinical Centre of
Excellence for Body, Mind and Health (Dutch abbreviation:
CLGG), a department of GGz Breburg, Tilburg, the Netherlands.
We assessed alexithymia at intake, and we assessed outcome
measures including depression, anxiety, physical symptoms, and
general functioning at intake before treatment and at discharge.
All patients who were referred to CLGG between August 2013
and April 2016 were included in the study.
The standard intake procedure at the CLGG consists of
questionnaire assessment during intake (referred to as baseline
measurement), case history assessment, physical assessment,
psychiatric evaluation, and psycho-diagnostic assessment. The
Bermond-Vorst Alexithymia Questionnaire (BVAQ) was self-
administered during the psycho-diagnostic assessment at intake.
Level of education was determined using Verhage coding (25),
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which includes seven levels ranging from low (levels 1 through
4), medium (level 5) to high (levels 6–7). Throughout treatment,
patient’s progress was evaluated using computerized Routine
Outcome Monitoring (ROM) (26). We used ROM data with
regard to depression, anxiety, physical symptoms and general
functioning scores. Patients were informed at intake about the
scientific research conducted at CLGG. Patients who did not give
their consent to use their data were excluded from the dataset.
Data were coded in order to create an anonymous dataset. The
Commission of Scientific Research of GGz Breburg approved of
this study (file number: CWO 2014-09).
Setting and Participants
Inclusion/exclusion criteria were evaluated for all patients that
were referred to CLGG. Inclusion criteria were (1) completion of
the intake, and (2) age at least equal to 18 years. Patients were
excluded if they (1) were engaged in personal or professional
injury procedures, (2) were not able to come to CLGG, (3) did not
complete questionnaires from the ROMduring intake and during
treatment, and (4) had an IQ below 80 [assessed during intake
using the Dutch Adult Reading Test (27)]. In addition, they were
excluded (5) if the primary treatment focus was not related to
physical symptoms. Other exclusion criteria were (6) presence of
psychosis or psychotic features that hampered treatment, (7) an
active suicide risk (threatening), and (8) substance dependency.
Comorbid conditions and DSM-5 classifications were assessed in
a clinical interview during intake.
Treatment at CLGG was of multimodal, in accordance
with the multidisciplinary guideline for medically unexplained
symptoms and somatic disorders (28, 29), and tailored to the
needs and treatment expectations of the patient. Treatment
consisted of cognitive behavioral therapy (CBT), acceptance
and commitment therapy (ACT), or problem solving treatment
(PST) provided by trained psychologists, in combination with
pharmacotherapy provided by a physician or psychiatrist.
The psychotherapeutic treatments were provided sequentially
and were tailored to the needs and treatment expectations
of the patients. During treatment, every 3 months both
psychotherapeutic and pharmacotherapeutic treatment were
adjusted based on progress in terms of PROM (24) and in a SDM
(25) bymultidisciplinary team consultation. Patients were treated
for 1 year on average, using this multimodal approach.
Figure 1 shows a flow chart of the study. Two hundred and
thirty-five patients filled out the BVAQ at intake. One patient,
who gave no consent, was excluded from the study. Of the
remaining 234 patients, 145 (62.0%) completed treatment. Of the
patients who completed treatment, 142 patients (97.9%) filled out
the Physical Symptom Checklist (PSC), 142 (97.9%) filled out
the Generalized Anxiety Disorder questionnaire (GAD-7), 144
(99.3%) filled out the Patient Health Questionnaire for assessing
depression (PHQ-9), and 126 (86.9%) filled out the 36-item Short
Form Health Survey (SF-36), both at intake and at discharge.
Instruments
We assessed depression, anxiety, physical symptoms, and general
functioning before, during and after treatment by means of
questionnaires with PROM. Alexithymia was only assessed at
intake.
Bermond-Vorst Alexithymia Questionnaire (BVAQ)
Alexithymia was assessed using the 40-item BVAQ (30). The
BVAQ provides valid and reliable measures of cognitive and
affective dimensions of alexithymia (30–34). The Toronto
Alexithymia Scale (35, 36), another instrument widely used in
alexithymia research, covers cognitive factors of alexithymia but
not affective dimensions. We preferred the BVAQ because it has
a broader scope.
Responses to the items were scored on a five-point Likert
scale. Higher scores indicate higher levels of alexithymia. The
BVAQ consists of five subscales containing eight items each. The
subscales are identifying, verbalizing, analyzing, fantasizing, and
emotionalizing, each in accordance with the five-factor model
of alexithymia (30). The five subscales constitute a cognitive
dimension and an affective dimension. Scores on the cognitive
dimension were obtained by adding the scores of the subscales
identifying, analyzing, and verbalizing (scores ranged from 24
through 120). Scores on the affective dimension were obtained by
adding the scores of the subscales emotionalizing and fantasizing
(scores ranged from 16 through 80). In our SSRD study sample,
coefficient alpha (37) for the cognitive dimension equaled 0.90
and for the affective dimension it equaled 0.68.
The Patient Health Questionnaire (PHQ-9)
Depression was assessed using the PHQ-9 (38). The PHQ-9 is
a reliable 9-item self-report questionnaire, with higher scores
indicating higher levels of depressive symptoms (38). Item scores
ranged from 0 (not at all) to 3 (nearly every day), and total scores
ranged from 0 to 27 (38). Cutoff points of 5, 10, 15, and 20
represent mild, moderate, moderately severe and sever levels of
depression (39).
Generalized Anxiety Disorder Questionnaire (GAD-7)
Anxiety was assessed using the GAD-7. The GAD-7 is a reliable
7-item self-report questionnaire that measures symptoms of
anxiety during the last 2 weeks (40). GAD-7 scores range from 0
to 21, and cutoff scores of 5, 10, and 15 represent mild, moderate
and severe levels of anxiety (39).
Physical Symptom Checklist (PSC)
Physical symptoms were measured using the PSC (41), which is a
51-item questionnaire. The total score on the PSC ranges from 0
to 51 and represents the number of physical symptoms that were
regularly or often present in the last week (41). De Waal and Van
Hemert (42) provided normative data.
36-Item Short Form Health Survey (SF-36)
We used the SF-36 (43) to assess general functioning. Studies
confirmed the SF-36’s validity and reliability (44–46). The SF-
36 is a self-report questionnaire that contains 36 items, which
are distributed across eight scales. Using the developers’ scoring
algorithm (47), the eight subscales were converted into two
summary measures, a physical component summary measure
(PCS) and amental component summarymeasure (MCS). Scores
range from 0 to 100, where higher scores on the PCS and MCS
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FIGURE 1 | Flowchart of patients included in the study. Sample sizes are given for patients who completed treatment and questionnaire assessment. BVAQ,
Bermond-Vorst Alexithymia Questionnaire.
indicate better general functioning. Normative data are available
in Maglinte, Hays (48).
Treatment Outcome Variables
Raw Change
For each outcome, a change score variable was created by
subtracting the score after treatment from the scores at intake.
This way, change scores represented treatment outcomes with
respect to depression, anxiety, physical symptoms, and general
functioning (PCS and MCS).
Reliable Change
To examine in more detail to what extent alexithymia predicts
reliable changes at the individual level, we adopted Jacobson
and Truax’ (49) framework. Using their reliable change index
(RCI), we determined which patients showed reliable change on
the PHQ-9, the GAD-7, the PSC, the PCS of the SF-36, or the
MCS of the SF-36. A dichotomous change variable was created,
reflecting change at a 90% confidence level; that is, scores equal
to 0 reflected no reliable change (i.e.,−1.645< RCI< 1.645) and
scores equal to 1 reflected reliable change (i.e., RCI < −1.645 or
RCI> 1.645).
Clinical Change
To further study the association between alexithymia and clinical
change at the individual level, we defined a categorical variable
called clinical remission. A patient shows clinical remission if
change is reliable and his/her score at intake exceeds a clinical
cutoff but not anymore after the treatment. The following clinical
cutoffs were used to define remission. For both the PHQ-9 and
GAD-7, we used a score of 5, which identifies at least mild
levels of depression or anxiety. For the PSC, we also used 5 as
the cutoff. This cutoff coincides with the 75th percentile of PSC
scores in normative data from general practitioner’s offices (42).
This means that remission is observed if after the treatment the
patient’s PSC score is no longer among the highest 25% in the
general population. To define remission on the PCS and MCS of
the SF-36, the mean scores in the general population were used
(48). In particular, the cutoffs for remission were 50 for the PCS
and 54 for the MCS after treatment. Furthermore, to speak of
clinical remission, patients must also have shown reliable change.
This results in a clinical change variable having three levels: 0 =
no reliable change (i.e., |RCI| < 1.645), 1 = reliable change but
no remission, and 2= remission.
Statistical Methods
Objective 1: Level of alexithymia was described by means of
normed scores. These normed scores were obtained using
normative data from the general population (50). In particular,
normed scores have a mean zero and a standard deviation equal
to 1. Positive norm scores suggest above average levels compared
to the general population. We used one-sample t-tests to test
whether mean differences between patients suffering from SSRD
and the normal group with respect to the normed scores were
significant.
Objective 2: We studied mean differences between the raw
scores at intake and at discharge for the PHQ-9, GAD-7, PSC,
and PCS and MCS of the SF-36, using the paired-sample t-tests,
for the complete group. For each outcome measure, effect-size
Cohen’s d was obtained following Rosner (51). Effect sizes equal
to d = 0.2 are considered small, d = 0.5 medium, and d ≥ 0.8
large (52).
Objective 3: We used linear regression analysis to explore
the association of alexithymia with depression, anxiety, physical
symptoms, and general functioning. The raw change-score
variables for the PHQ-9, the GAD-7, the PSC, the PCS of the SF-
36, and the MCS of the SF-36 were used as dependent variables.
We used multinomial logistic regression to explore the
association of alexithymia with clinical change for depression,
anxiety, physical symptoms, and general functioning. Logistic
regression and multinomial regression analysis provide insight
into the predictive value of alexithymia in the clinical context.
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Objective 4: Chronic medical condition and the two
interaction terms of the dimension of alexithymia with chronic
medical condition were used as independent variables in
regression models.
We used logistic regression to investigate if the cognitive
and affective dimensions, chronic medical condition, and the
interactions between the dimensions of alexithymia and chronic
medical condition predict reliable change at the individual level.
For each outcome variable, the regression analyses were done
as follows. First, we estimated the full model that included as
predictors the background variables (age, gender, and education
level), the first-order effects of the cognitive and affective
alexithymia dimensions, and chronic medical conditions, and
the interaction effects between the alexithymia dimensions and
medical conditions. To study the interaction effects, we centered
the independent variables to avoid potential problems with
respect to multicollinearity (53). Second, in case some of the
interaction effects were non-significant, we re-estimated the
model without the non-significant interaction effects.
For logistic regression analysis, we used Nagelkerke’s R-square
to gauge effect size. Formally, the pseudo R-square does not
represent proportions of explained variance, but we interpreted
the pseudo R-square as if it did provide the proportion of the
variation the model explained (54). We used the guidelines
of Cohen (? ) to interpret Nagelkerke’s pseudo R-square (i.e.,
R-square = 0.02 was considered small, R-square = 0.13 was
considered medium, R-square ≥ 0.26 was considered large). All
analyses were done by means of the Statistical Package for the
Social Sciences version 22 (55).
RESULTS
Sample Characteristics
Two hundred and two patients (86.3%) were diagnosed with a
somatic symptom disorder, 10 patients (4.3%) were diagnosed
with an illness anxiety disorder, and 22 patients (9.4%) were
diagnosed with a conversion disorder.
Table 1 (upper panel) describes the socio-demographic
characteristics of the SSRD patient sample. The SSRD sample
consisted of 234 patients (59.0% females). The sample had amean
(M) age of 42.8 [standard deviation (SD) = 12.56; range: 19 to
79]. Seven patients had missing values on the BVAQ items. One
of these patients had six missing item scores and was excluded
from further analyses. The only missing item score for the
remaining six patients was imputed using two-way imputation
(56, 57).
The level of alexithymia of patients suffering from SSRD
compared to known norm scores for the general population.
Table 1 (lower panel) shows the means for the raw scores
(column 2) and normed scores (column 5) on the BVAQ.
Using a significance level equal to 0.007 (alpha of 0.05 divided
by 7, equal to the number of used tests), significant mean
differences with respect to the norm scores were found for
the subscales verbalizing [t(233) = 4.239, p < 0.001],
fantasizing [t(233) = 3.770, p < 0.001], identifying
[t(233) = 7.759, p < 0.001], and emotionalizing [t(233) =
−8.106, p < 0.001]. A significant mean difference was
found for the cognitive dimension [t(233) = 4.944, p <
0.001]. For the subscales of the cognitive dimension, we found
elevated levels of identifying (M = 0.69; range −1.97 to 4.26)
and verbalizing (M = 0.39; range −2.87 to 3.08) compared to
the general population. No significant mean differences were
found between SSRD patients and the general population for
analyzing [t (233) = −0.500, p = 0.618] and the affective
dimension [t (233) = −1.632, p = 0.104]. For the subscales
of the affective dimension in the BVAQ, we found lowered
levels of emotionalizing (M = −0.55; range −2.96 to 2.48), but
higher mean values for fantasizing (M = 0.27; range −2.51 to
2.42).
Treatment outcomes of a multimodal treatment tailored to
patients needs by SDM and PROM in terms of depression, anxiety,
physical symptoms, and general functioning.
Table 2 shows the mean scores before and after treatment
for the PSC, GAD-7, PHQ-9, and the MCS and PCS of the
SF-36. Results suggested substantive mean improvements of the
treatment outcomes. PSC means before and after treatment
improved significantly [t (141) = 4.207, p < 0.001, d = 1.82],
the mean scores on the PHQ-9 also differed significantly before
and after treatment [t (143) = 4.837, p < 0.001, d = 1.43], and
the mean scores on the GAD-7 differed significantly before and
after treatment [t (141) = 5.090, p < 0.001, d = 1.21]. Mean
MCS and PCS scores for the SF-36 did not differ significantly
before and after treatment [respectively, t (125) = 0.757, p =
0.450, d = 0.92 and t (126) = 1.494, p = 0.138, d = 1.06].
The association of alexithymia with treatment outcomes in
terms of depression, anxiety, physical symptoms, and general
functioning.
Alexithymia had significant association with treatment
outcome regarding anxiety (Table 3). The cognitive and affective
dimensions did not significantly predict change with respect
to depression, physical symptoms scores, and general health
functioning.
Table 4 shows the results of the logistic regression analyses.
The cognitive dimension had a significant negative main
association on treatment outcome with respect to anxiety
(Odds Ratio (OR) = 1.02, 95%CI = [1.00, 1.05]). The squared
semi-partial correlation for this dimension was 0.05, which
means that 5% of the total variability of the treatment outcome
for anxiety is uniquely associated with the cognitive dimension.
The affective dimension was associated with a significant positive
association on treatment outcome with respect to general mental
health functioning (OR = 1.25, 95%CI = [1.09, 1.44]).
Removing the affective dimension decreased R-square to .15,
which renders the association substantial.
Table 5 shows the results for predicting reliable and clinical
change. With regard to general functioning (MCS of the SF-36),
the affective dimension was significantly associated with clinical
change in the group of patients with no remission vs. the group
of patients with no clinical change and no remission (OR =
1.24, 95%CI = [1.08, 1.42]). Results for clinical change and
remission vs. no clinical change and no remission could not be
computed, because none of the patients showed remission on
the MCS. No significant associations were found between anxiety
and for the PCS of the SF-36.
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TABLE 1 | Socio-demographic characteristics and descriptive statistics for the BVAQ in the SSRD sample at intake (N = 234).
Characteristic M (SD) Min/Max n (%) Normed scoresa (min/max) p
BACKGROUND VARIABLES
Gender
Men 96 (41.0)
Women 138 (59.0)
Age 42.78 (12.56) 19/79
Educational level*
Low (1–4) 56 (24.9)
Medium (5) 103 (45.8)
High (6–7) 66 (29.2)
(Missing value) (9)
Marital status
Married/living together 150 (71.4)
Divorced 11 (5.2)
Widow(er) 1 (0.5)
Single 48 (22.9)
(Missing value) (24)
PSC 16.57 (8.08) 0/38
GAD-7 11.51 (5.47) 0/21
PHQ-9 14.21 (6.07) 0/27
SF-36 (n = 225)b
PCS 40.48 (5.44) 27.49/57.43
MCS 44.01 (5.16) 21.30/55.55
Comorbidity at intake
Comorbid anxiety 2 (0.9)
Comorbid depression 25 (11.4)
Comorbid depression and anxiety 193 (87.7)
BVAQ SCORES
Cognitive dim. 67.12 (17.64) 32/106 0.43 (−2.38/3.25) < 0.001
Identifying 22.10 (7.02) 8/40 0.69 (−1.97/4.26) < 0.001
Analyzing 19.61 (6.02) 8/34 −0.04 (−2.52/2.97) 0.618
Verbalizing 25.41 (8.29) 8/40 0.39 (−2.87/3.08) < 0.001
Affective dim. 45.48 (8.88) 19/66 −0.10 (−2.79/2.45) 0.104
Fantasizing 26.74 (6.92) 8/40 0.27 (−2.51/2.42) < 0.001
Emotionalizing 18.74 (5.16) 8/32 −0.55 (−2.96/2.48) < 0.001
SSRD, Somatic Symptom and Related Disorders; PSC, Physical Symptom Checklist; GAD-7, Generalized Anxiety Disorder questionnaire; PHQ-9, Patient Health Questionnaire; SF-36,
36-item Short Form Health Survey; MCS, Mental Component Summary; PCS, Physical Component Summary; BVAQ, Bermond-Vorst Alexithymia Questionnaire.
aNormed scores were based on normative data (50).
b225 participants of the whole sample completed the SF-36.
*Using Verhage coding (25).
Influence of chronic medical conditions (e.g., diabetes mellitus,
cardiovascular diseases, and others) on the association between
alexithymia and treatment outcome.
The cognitive dimension and medical condition showed a
significant interaction association (see Table 3). Simple effects
analysis suggested a negative association for patients without a
chronic medical condition (B = −0.08, p = 0.022), and a
non-significant association for patients with a chronic medical
condition (B = 0.04, p = 0.329).
The interaction between the cognitive dimension and chronic
medical condition had a significant association with reliable
change with regard to depression (OR = 0.95, 95%CI =
[0.91, 0.99]) (Table 4). The squared semi-partial correlation for
this interaction was 0.06, which means that 6% of the total
variability of treatment outcome for depression is uniquely
associated with the interaction between cognitive dimension of
alexithymia and chronic medical condition. The OR equal to
0.95 suggests that the association between alexithymia (cognitive
dimension) and treatment outcome in terms of depression is
negative for patients with chronicmedical condition compared to
patients without a chronic medical condition. Nevertheless, these
correlations andORs are very small and we render them clinically
irrelevant.
Regarding physical symptoms, a significant interaction effect
between cognitive dimension and chronic medical condition was
found for the PSC (OR = 0.95, 95%CI = [0.91, 1.00]).
The OR equal to 0.95 suggests that the association between
alexithymia (cognitive dimension) and treatment outcome in
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TABLE 2 | Mean scores on the PHQ-9, GAD-7, PSC, and SF-36 of the SSRD
sample at intake and after treatment.
Outcome measure N Measurement occasion
At intake After treatment
M SD M SD p
PSC 142 16.26 7.68 13.54 9.22 <0.001
GAD-7 142 11.18 5.41 9.09 6.17 <0.001
PHQ-9 144 13.94 6.12 11.50 7.36 <0.001
SF-36 126
PCS 41.10 5.44 40.42 5.48 0.138
MCS 43.47 5.73 43.03 5.82 0.450
M,Mean; SD, Standard Deviation; PHQ-9, Patient Health Questionaire-9; GAD-7, General
Anxiety Disorder questionnaire; PSC, Physical Symptom Checklist; SF-36, 36-item Short
Form Health Survey; MCS, Mental Component Summary; PCS, Physical Component
Summary.
n = the number of patients who completed the treatment and who filled out the
questionnaire both at intake and after treatment.
TABLE 3 | Linear regression of raw change scores for the GAD-7 on the BVAQ
dimensions and covariates.
Predictors Change scores for the GAD-7
B 95% CI P
Cognitive
dimension
−0.08 [−0.15, −0.01] 0.021
Affective
dimension
−0.01 [−0.13, 0.12] 0.911
Chron med
cond
0.76 [−0.97, 2.49] 0.386
Int cogn_med 0.12 [0.02, 0.22] 0.022
Int aff_med −0.15 [−0.35, 0.05] 0.140
GAD-7, Generalized Anxiety Disorder questionnaire; 95% CI, 95% confidence interval for
B; Chron med cond, chronic medical condition; Int cogn_med, interaction between the
cognitive dimension of alexithymia and chronic medical condition; Int aff_med, interaction
between the affective dimension and chronic medical condition.
All coefficients in bold are significant at the 5% significance level.
terms of physical symptoms is negative for patients with chronic
medical condition compared to patients without a chronic
medical condition. The squared semi-partial correlation for
this interaction was 0.05, which means that 5% of the total
variability of treatment outcome for physical symptoms is
uniquely associated with this interaction.
Table 5 shows the results for predicting reliable and clinical
change. Regarding depression, the interaction between the
cognitive dimension and chronic medical condition is significant
in patients with clinical change and no remission vs. patients with
no clinical change and no remission (OR = 0.94, 95%CI =
[0.89, 0.99]). The interaction between the affective dimension
and chronic medical condition is significant in patients with
clinical change and no remission vs. patients with no clinical
change and no remission (OR = 1.12, 95%CI = [1.00, 1.24]).
To conclude, our results suggest some associations of
alexithymia with clinical change and the influence of chronic
medical condition on the association between alexithymia and
treatment outcome with respect to depression, anxiety, physical
symptoms, and general functioning. However, the estimated ORs
of ∼1.00 suggests that these associations are very small and
negligible.
DISCUSSION
Main Findings
Alexithymia in patients suffering from SSRD was compared
to normative data for the general population. The scores of
SSRD patients on emotionalizing were lower compared to the
norm scores, while elevated scores were found for other BVAQ
subscales. The results suggest that SSRD patients show reduced
abilities to identify, verbalize, and fantasize, and tend to be
aroused by emotional events. This confirms the first hypothesis.
The results also suggest that patients suffering from SSRD
improve after multimodal and tailored treatment with regard to
anxiety, depression, and physical symptoms (Cohen’s d ranged
1.21–1.82). This confirms the second hypothesis.
Even though our results suggest some associations of
alexithymia with treatment outcome, the odds ratios were close
to 1.0 (range 1.02–1.25). Therefore, we render the association
of alexithymia not clinically relevant with regard to treatment
outcome in terms of depression, anxiety, physical symptoms, and
general functioning. This is not what we expected based on the
literature.
The cognitive dimension of alexithymia affects treatment
outcomes for patients suffering from chronic medical condition
but not for patients free of chronic medical conditions with
regard to depression and physical symptoms, but odds ratios
were equal to 0.95 so we render the association also not clinically
relevant. This is not what we expected.
SSRD patients in this study received multimodal treatment
tailored to the patients’ needs in a SDMmodel based on repeated
PROM, and improved significantly after treatment. However, the
level of alexithymia at baseline was not associated with a clinically
relevant difference in treatment outcome, although our results
suggested that SSRD patients have difficulties with identification
and verbalization of emotions. Two possible explanations are the
following. First, as treatment outcome was positive independent
of suffering from alexithymia, it might be that alexithymia is not a
clinically relevant factor needing specific attention when treating
patients with SSRD. This might be a possible explanation, if
in a randomized clinical trial design the positive association of
this multimodal treatment model would be confirmed and again
the association with alexithymia would be clinically irrelevant.
Second, it could be that the treatment, although yielding positive
outcomes, could have better outcomes for patients with high
alexithymia scores if the treatment would address them. In that
case, treatment should focus on improving identification and
verbalization of emotions (6).
Treatment options for SSRD include affective mentalizing
as prominent factor because affective mentalization is involved
in the onset and prolongation of physical symptomatology and
the interpersonal problems that co-occur with these physical
symptoms (58, 59). The link between emotional states and
bodily distress and how to restore this link could be improved
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TABLE 4 | Logistic regression analyses predicting reliable change regarding depression, physical symptoms, and general functioning.
Predictors Outcome variable
Depression (PHQ-9) Anxiety (GAD-7) Physical symptoms
(PSC)
General functioning
(MSC of the SF-36)
OR 95% CI R2a OR 95% CI R2a OR 95% CI R2a OR 95% CI R2a
0.10 0.08 0.14 0.43
Cogn dim 1.03 [1.00, 1.06] 1.02 [1.00, 1.05] 1.01 [0.98, 1.04] 1.00 [0.96, 1.04]
Aff dim 1.03 [0.98, 1.09] 0.98 [0.94, 1.03] 0.99 [0.94, 1.05] 1.25 [1.09, 1.44]
Chron med cond 1.06 [0.50, 2.26] 0.93 [0.45, 1.92] 1.38 [0.63, 2.98] 0.42 [0.08, 2.28]
Cogn × medical
condition
0.95 [0.91, 0.99] – – 0.95 [0.91, 1.00] – –
Aff × medical
condition
1.01 [0.92, 1.10] – – 1.10 [1.00, 1.21] – –
PHQ-9, Patient Health Questionnaire; GAD-7, Generalized Anxiety Disorder questionnaire; PSC, Physical Symptom Checklist; MCS, Mental Component Summary; SF-36, 36-item
Short Form Health Survey; OR, Odds Ratio; 95% CI, 95% confidence interval; Chron med cond, chronic medical condition; Int cognmed, interaction term of the cognitive dimension of
alexithymia and chronic medical condition; Int aff, interaction term of the affective dimension and chronic medical condition.
Results for chronic medical condition, and for the interaction terms of the alexithymia dimension and chronic medical condition (Model 3 and 4; respectively) yielded no significant results.
aNagelkerke’s pseudo R-square.
All coefficients in bold are significant at the 5% significance level.
TABLE 5 | Multinomial logistic regression analyses predicting clinical change regarding depression, physical symptoms, and general functioning.
Predictors Depression
(PHQ-9)
Physical symptoms
(PSC)
General
functioning
(MCS of the SF-36)
OR 95% CI p OR 95% CI p OR 95% CI p
CLINICAL CHANGE/NO REMISSION vs. NO CLINICAL CHANGE/NO REMISSION
Affective dimension 1.02 [0.95, 1.09] 0.561 1.00 [0.94, 1.06] 0.880 1.24 [1.08, 1.42] 0.003
Cognitive dimension 1.03 [1.00, 1.07] 0.091 1.01 [0.98, 1.04] 0.572 0.90 [0.95, 1.04] 0.630
Chron med cond 0.86 [0.33, 2.22] 0.751 1.25 [0.53, 2.94] 0.618 0.39 [0.07, 2.12] 0.276
Int aff_med 1.00 [0.89, 1.11] 0.944 1.12 [1.00, 1.24] 0.048 – – –
Int cogn_med 0.94 [0.89, 0.99] 0.021 0.95 [0.91, 1.00] 0.054 – – –
CLINICAL CHANGE/REMISSION vs. NO CLINICAL CHANGE/NO REMISSION
Affective dimension 1.03 [0.95, 1.12] 0.424 1.01 [0.90, 1.15] 0.822 – – –
Cognitive dimension 1.02 [0.98, 1.07] 0.301 1.00 [0.94, 1.07] 0.977 – – –
Chron med cond 1.46 [0.52, 4.12] 0.613 1.19 [0.22, 6.40] 0.836 – – –
Int aff_med 0.97 [0.91, 1.02] 0.230 1.03 [0.86, 1.25] 0.732 – – –
Int cogn_med 1.03 [0.91, 1.16] 0.643 0.95 [0.87, 1.05] 0.319 – – –
PHQ-9, Patient Health Questionnaire; PSC, Physical Symptom Checklist; MCS, Mental Component Summary; SF-36, 36-item Short Form Health Survey; OR, Odds Ratio; 95% CI, 95%
confidence interval; Chron med cond, chronic medical condition; Int cogn_med, interaction term of the cognitive dimension of alexithymia and chronic medical condition; Int aff_med,
interaction term of the affective dimension and chronic medical condition.
Results not reported because interaction effect was not significant, or effect could not be estimated because no patients showed remission on the MCS.
All coefficients in bold are significant at the 5% significance level.
by enhancing ones capacity of emotional awareness. A recent
study suggested that women with fibromyalgia might benefit
from an emotional disclosure or expression intervention (60).
Our results suggested that SSRD patients have difficulties
with identification and verbalization of emotions. Therefore,
treatment of SSRD patients should focus on improving
identification and verbalization of emotions which was also
suggested by a previous study (6).
Nevertheless, based on our results we conclude that the
influence of alexithymia is clinically irrelevant. Previous studies
also found a relationship between alexithymia and interpersonal
dysfunction, aggression, and personality disorders (61–63). This
association is not yet explored amongst patients suffering
from SSRD. Personality characteristics such as interpersonal
dysfunction, aggressive behavior or coping strategies may also
increase insights in the personal characteristics of patients
suffering from SSRD and might offer treatment options.
Studies focusing on these kinds of personality characteristics
are warranted in order to establish such new therapies.
Future studies should also include other patient groups (e.g.,
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depressed patients), to explore differences in emotion regulation
between patients having SSRD and other patients. This way,
researchers are able to explore whether or not impoverished
emotional regulation is a specific feature of SSRD or a
common feature of patients suffering from other mental
disorders.
Strengths and Limitations of the Study
The use of norm scores of a large sample from the general
population as a reference group accounts as a major strength,
because gender and age-specific norms could be used from
a large and representable group. Furthermore, the sample
consisted of consecutive patients visiting a Clinical Centre
of Excellence for patients with Somatic Symptom Disorder,
who were referred by their general practitioner, their medical
specialist or their psychiatrist or psychotherapist after an average
treatment duration of 7 years without solace. The patients
had high complexity levels at biological and psychological
symptom levels (64), suffered from comorbidity, complex
treatment histories, and high levels of social vulnerability.
Hence, this study provides us with findings relevant for such
a patient group with SSRD, but results may not necessarily be
generalizable to the general population. However, although the
composition of patient populations may differ across regions,
it is unlikely that the underlying mechanisms of treatment
outcome differ across specialty mental health institutions.
Unfortunately, our sample was too small to explore the
relationship between alexithymia with treatment outcome for
different SSRD categories (e.g., somatic symptom disorder and
illness anxiety disorder). Our sample was heterogeneous with
respect to SSRD diagnoses. Furthermore, we did not include
neuropsychological aspects in this study whom may have
negatively influence treatment outcome since patients suffering
from SSRD experience significant cognitive problems (65).
Implications for Research
Future studies on the relationship between alexithymia
and treatment outcome should differentiate between
SSRD categories. Future studies should also include large
samples and evaluate effectiveness of multimodal tailored
treatment supported by SDM and PROM in a randomized
design.
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